Maintaining primary AML cells ex vivo remains technically challenging due to their limited proliferative capacity and dependence on niche-derived cytokines such as SCF, IL-3, and FLT3 ligand [69,74,75]. This evidence concerns the gene FLT3 and acute myeloid leukemia.